RxDoctor Payments Data

Alison Cieszko, PA

Medical · Greenville, NCNPI 1952387771

Payments from drug & device makers

$3,928in general payments, 2019–2025

Across 240 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$858
  • Actelion Pharmaceuticals US, Inc.$615
  • AstraZeneca$379
  • Bayer$379
  • E.r. Squibb & Sons, L.L.C.$371
  • Novartis$255
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$2005%
  • Food & beverage$3,60692%
  • Education$1223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,928 in reported general payments places this provider in the 85th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$28,332
Medicare patients
159
Services billed
572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan127$123,160
FarxigaDapagliflozin Propanediol58$61,500
EliquisApixaban46$41,343
XareltoRivaroxaban30$31,192
JardianceEmpagliflozin22$26,432
Repatha PushtronexEvolocumab13$8,652
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine11$4,027
Bumetanide43$1,633
Torsemide41$1,631
Sildenafil Citrate20$1,293
Spironolactone146$814
Atorvastatin Calcium87$722
Metoprolol Succinate73$596
Carvedilol78$522
Furosemide87$496

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$255$123,160127 claims
AstraZenecaFarxiga$379$61,50058 claims
PfizerEliquis$246$41,34346 claims
Johnson & JohnsonXarelto$161$31,19230 claims
Boehringer IngelheimJardiance$172$26,43222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 878 medical providers in North Carolina.

Other medical in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →